Navigation Links
Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance
Date:2/22/2011

nted in Japan and Canada and one for the liposomal formulation of TELINTRA granted in Canada. Three other patents covering novel TELINTRA analogs were granted in Singapore and Chile.
  • Publication of a review in the journal, Cell Death and Differentiation: Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death. This review describes recent advances in the understanding of the important role that the enzyme GSTP1-1 plays in the progression of cancer and other diseases associated with increased cell proliferation. TELINTRA, inhibitor of GSTP1-1, has recently been reported to show positive results in a Phase 2 trial in patients with MDS, a disease characterized by disordered cell proliferation and differentiation.
  • Publication of a case report by Quddus et al., Oral Ezatiostat Hydrochloride (TELINTRA®) and Myelodysplastic Syndrome (MDS): A case report of sustained hematologic response following an abbreviated exposure Journal of Hematology & Oncology 2010, 3:16. This case report describes a patient who experienced a sustained hematologic response in all three blood cell lines continuing for over a year, after an abbreviated course of oral TELINTRA received while on the current Phase 2 Study in Low to Intermediate-1 Risk MDS.

  • In 2011, Telik is focusing its resources on: (1) advancing the clinical development of TELINTRA in MDS including the completion of the ongoing Phase 1 TELINTRA combination trial with lenalidomide, (2) seeking corporate partnerships for development and commercialization of its drug product candidates, (3) advancing its leading preclinical oncology drug candidates and (4) supporting TRAP® research collaborations.

    Financial Outlook

    For the full year 2011, Telik anticipates total operating costs and expenses to be in the range of $13.0 million to $15.0 million, which includes stock-based compensation expense of approximately $1.3 millio
    '/>"/>

    SOURCE Telik, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related medicine technology :

    1. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
    2. Telik Announces Preclinical Data Demonstrating Anti-Cancer Activity of Dual Inhibitors of Aurora Kinase and VEGFR2
    3. Telik Announces Telintra Presentation at American Society of Hematology Annual Meeting
    4. Telik Announces Initiation of Two Phase 2 Randomized TELINTRA Studies
    5. Teliks Proteasome Inhibitor Program Meets a Preclinical Development Milestone
    6. Telik Announces Presentation at ASCO Annual Meeting
    7. Telik Announces Publication of Positive Phase 1 Results of a Multicenter Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets In Patients With Myelodysplastic Syndrome
    8. Telik Announces Publication of Positive Phase 1-2a Results of a Multicenter Study of TELCYTA(R) in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer
    9. Telik Announces Initiation of Phase 1 Clinical Study of Ezatiostat Hydrochloride (TELINTRA(R), TLK199) Tablets in Combination With Lenalidomide (Revlimid(R)) in Patients With Myelodysplastic Syndrome (MDS)
    10. Telik Announces Third Quarter 2009 Financial Results
    11. Telik Announces Fourth Quarter and 2009 Year End Financial Results and 2010 Financial Guidance
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/2/2015)... Sept. 2, 2015 STAAR Surgical Company (NASDAQ: ... lenses and delivery systems for the eye, today announced that ... to the Company,s Board. Mr. Wall ... Boston -based investment firm, for more than nine ... of Directors, and chair of the Corporate Governance Committee and ...
    (Date:9/2/2015)... , Sept. 2, 2015   Physicians Rx ... Bernstein has joined the organization as President and ... recently served as President and Chief Executive Officer for ... Chief Executive Officer of Physicians Rx Pharmacy, be responsible ... "We are extremely pleased to bring Gaston on ...
    (Date:9/2/2015)... Research and Markets ( http://www.researchandmarkets.com/research/l8z67c/pharmaceutical ) has announced ... (Basel, Switzerland - November 26-27, 2015)" conference to their ... overview of the key areas of pharmaceutical regulatory affairs in ... , Macau and Taiwan ... important aspects of gaining and maintaining a successful Marketing Authorisation ...
    Breaking Medicine Technology:William P. Wall Appointed to STAAR Surgical Board of Directors 2Gaston L. Bernstein Named President and CEO of Physicians Rx Pharmacy 2Pharmaceutical Regulatory Affairs in China Seminar: Basel, Switzerland - November 26-27, 2015 2
    ... Tim Wentworth, group president for employer and key ... MHS ), is scheduled to present at the Lazard ... 17, 2010 in New York. (Logo: http://photos.prnewswire.com/prnh/20100609/MEDCOLOGO) ... The St. Regis Hotel is scheduled to begin at ...
    ... Despite national guidelines recommending that inhaled corticosteroid (ICS) ... with mild persistent asthma, a new study finds that ... drugs that combine an ICS and a long-acting beta ... noted based on pharmacy and medical claims. The analysis ...
    Cached Medicine Technology:Medco to Present at the Lazard Capital Markets 7th Annual Healthcare Conference 2New Study: Overuse of Combination Drug Therapy in Patients with Mild Asthma Leads to Increased Costs 2New Study: Overuse of Combination Drug Therapy in Patients with Mild Asthma Leads to Increased Costs 3New Study: Overuse of Combination Drug Therapy in Patients with Mild Asthma Leads to Increased Costs 4
    (Date:9/2/2015)... ... September 02, 2015 , ... ... in the news recently following a decision by the Centers for Medicare & ... likely to average approximately $71,000 or roughly 40% of its headline-grabbing $178,000 price ...
    (Date:9/2/2015)... ... 02, 2015 , ... Date and time: Oct. 3, 2015, 9 a.m. to ... Tomlinson Road, Bryn Athyn, Pa 19009 , Cost: $50 per person; includes lunch , ... Times best-selling author Sam Keen based on his new book which he co-authored with ...
    (Date:9/2/2015)... CA (PRWEB) , ... September 02, 2015 , ... In ... featured by the Huffington Post on August 25th, writer Akela Stanfield detailed her lifelong ... While the author acknowledged that she had always seen herself as someone who would ...
    (Date:9/2/2015)... ... September 02, 2015 , ... ... endpoint data collection, cloud analytics and workflow solutions today announced the September ... pharmaceutical researchers to participate in interactive programs in which ERT scientists and ...
    (Date:9/2/2015)... , ... September 02, 2015 , ... ... healthcare industry announced today the launch of its enhanced, cloud-based mobile ePrescribing application. ... look” and focus on improving prescriber usability. A leader in health technology, RxNT ...
    Breaking Medicine News(10 mins):Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 2Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 3Health News:Analysis Shows Amgen’s Leukemia Drug, Blincyto, Will Cost 60% Less than Highly Publicized $178,000 Price Tag 4Health News:justCommunity, Inc. and Bryn Athyn Men’s Groups Present Workshop on Family Reconciliation 2Health News:Recent Editorial on Bariatric Surgery Acceptance Illuminates a Typical Journey Towards Weight Loss Surgery, Notes Dr. Michael Feiz 2Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 2Health News:ERT Announces Web Seminar Series on Optimizing Trial Data Collection & Gaining Real-Time Data Insights 3Health News:RxNT Releases Enhanced ePrescribing iPhone App to Improve Prescriber Usability 2
    ... New analyses from the Women,s Health Initiative (WHI) confirm that ... healthy postmenopausal women. Researchers report a trend toward an ... of hormone therapy among women who began therapy within 10 ... among women who began hormone therapy more than 10 years ...
    ... disease activity when added to interferon beta , TUESDAY, ... to standard treatment with interferon beta may reduce multiple ... new study reports. , Previous non-randomized studies found that ... disease activity. , This new phase 2 study ...
    ... ... 2010 , ... February 16, 2010 -- Aberdeen Group, a Harte-Hanks Company has released a new benchmark ... Telecom Expense Management (TEM) solutions as a strategic foundation and precursor for other ...
    ... ... all natural food service company manages to grow sales and reduce its ... second year in a row, Service Foods, the largest Home Food service ... after increasing sales. Verus Carbon Neutral once again measured and offset 100% ...
    ... ... Texas, has contracted with Atlanta-based Premier Anesthesia to manage the anesthesia services for its ... ... hospital in east Texas, has contracted with Atlanta-based Premier Anesthesia to manage the anesthesia ...
    ... ABBOTT PARK, Ill., Feb. 16 Abbott (NYSE: ... EUR 4.5 billion ( $6.2 billion ) acquisition of ... portfolio of pharmaceutical products and expanding Abbott,s presence in key global ... Abbott expects the acquisition to add approximately $2.9 billion ...
    Cached Medicine News:Health News:WHI data confirm short-term heart disease risks of combination menopausal hormone therapy 2Health News:WHI data confirm short-term heart disease risks of combination menopausal hormone therapy 3Health News:WHI data confirm short-term heart disease risks of combination menopausal hormone therapy 4Health News:Added Drug Aids MS Treatment 2Health News:AnchorPoint Sponsored Aberdeen Group Report Addresses Telecom Lifecycle Management 2Health News:AnchorPoint Sponsored Aberdeen Group Report Addresses Telecom Lifecycle Management 3Health News:AnchorPoint Sponsored Aberdeen Group Report Addresses Telecom Lifecycle Management 4Health News:AnchorPoint Sponsored Aberdeen Group Report Addresses Telecom Lifecycle Management 5Health News:Service Foods Reduces its Carbon Footprint and Grows Sales 2Health News:Service Foods Reduces its Carbon Footprint and Grows Sales 3Health News:Premier Anesthesia Forges New Partnership with Texas Hospital 2Health News:Abbott Completes Acquisition of Solvay Pharmaceuticals 2Health News:Abbott Completes Acquisition of Solvay Pharmaceuticals 3
    Cer-Met series II system....
    The Ceracup has a standard profile plastic component with a ceramic insert and the benefit of alumina-alumina contact....
    S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
    S-ROM acetabular cups provide a variety of geometrical options to help address many anatomical situations and defects....
    Medicine Products: